Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
07:14pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device
03:48pm, Thursday, 05'th Jan 2023
Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.
Could Eli Lilly Stock Help You Become a Millionaire?
03:07pm, Thursday, 05'th Jan 2023 The Motley Fool
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%.
Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab
12:41pm, Thursday, 05'th Jan 2023 MarketWatch
A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021
Biogen Names Priya Singhal as Executive Vice President, Head of Development
12:30pm, Thursday, 05'th Jan 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of
Biogen separates research and development into two functions
08:03am, Thursday, 05'th Jan 2023
Biogen Inc. BIIB, -0.67% said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya Singhal, currently the head of global
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:00pm, Tuesday, 03'rd Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.
Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab
02:47pm, Tuesday, 03'rd Jan 2023
The Food and Drug Administration is expected to make a decision on whether to approve a new Alzheimer's disease medication the week after a damning new report found the regulator didn't follow the cor
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond
02:37pm, Tuesday, 03'rd Jan 2023 The Motley Fool
This company's best asset may be its pipeline.
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease
05:22pm, Friday, 30'th Dec 2022
Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths.
House Democrats fault FDA for collaborating improperly with Biogen
09:26am, Friday, 30'th Dec 2022
A new report from House Democrats found that the U.S. Food and Drug Administration inappropriately collaborated with Biogen before approving its Alzheimer's treatment Aduhelm. CNBC's 'Squawk Box' team
12 Stocks Turned $10,000 To $277,126 In 12 Months
08:00am, Friday, 30'th Dec 2022
Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.
House committee questions Biogen drug approval process
12:20am, Friday, 30'th Dec 2022
The FDA's approval process of Biogen's Alzheimer's drug was questioned in a Congressional report released Thursday.
3 Biotech Stocks to Watch Heading Into 2023
02:49pm, Thursday, 29'th Dec 2022
Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.
